Evoke Pharma’s shares surged on Monday after the company presented real-world data showing that GIMOTI (metoclopramide nasal spray) significantly improves healthcare resource utilization for patients with diabetic gastroparesis who are also using GLP-1 receptor agonists. The study highlights GIMOTI’s potential to reduce healthcare costs and improve outcomes for patients.